170847-28-6

Basic information

• Product Name: 3-(4-Methoxyphenyl)-4-[4-(2-dimethylaminoethoxy)benzoyl]-1,2-dihydronaphthalene, Citrate Salt
• Synonyms: 3-(4-Methoxyphenyl)-4-[4-(2-dimethylaminoethoxy)benzoyl]-1,2-dihydronaphthalene, Citrate Salt
• CAS NO: 170847-28-6
• Molecular Weight: 619.668
• Mol File: 170847-28-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-(4-Methoxyphenyl)-4-[4-(2-dimethylaminoethoxy)benzoyl]-1,2-dihydronaphthalene, Citrate Salt(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Methoxyphenyl)-4-[4-(2-dimethylaminoethoxy)benzoyl]-1,2-dihydronaphthalene, Citrate Salt(170847-28-6)
• EPA Substance Registry System: 3-(4-Methoxyphenyl)-4-[4-(2-dimethylaminoethoxy)benzoyl]-1,2-dihydronaphthalene, Citrate Salt(170847-28-6)

Safety Data

• Hazardous Substances Data: 170847-28-6(Hazardous Substances Data)

Upstream product

• 63619-83-0 3-(4-methoxyphenyl)-4-(4-hydroxybenzoyl)-1,2-dihydronaphthalene 
• 5949-29-1 citric acid monohydrate 

Relevant articles and documents

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods for treating resistant tumors

The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein. Another embodiment of this invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.